Scapa Group rises as revenues soar

AIM-listed medical and industrial adhesives company Scapa Group (LON:SCPA) has seen its share price climb by 5.61% to 207p (as of 15:20 BST) after statutory revenues for the half year ended 30th September rose by 14.3%. Statutory profits for the period are expected to be 17% below last year, due to the loss of the ConvaTec contracts.

The healthcare division continues to drive the improvement in sales, and management said that the second half would see further uplift from new products and technology transfers.